Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?
Corresponding Author
Dr M. Flint Beal MD
Neurology Service, Massachusetts General Hospital and Harvard Medical School, Boston, MA
Neurology Research 4, Massachusetts General Hospital, Boston, MA 02114Search for more papers by this authorCorresponding Author
Dr M. Flint Beal MD
Neurology Service, Massachusetts General Hospital and Harvard Medical School, Boston, MA
Neurology Research 4, Massachusetts General Hospital, Boston, MA 02114Search for more papers by this authorAbstract
The etiology of nerve cell death in neuronal degenerative diseases is unknown, but it has been hypothesized that excitotoxic mechanisms may play a role. Such mechanisms may play a role in diseases such as Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Alzheimer's disease. In these illnesses, the slowly evolving neuronal death is unlikely to be due to a sudden release of glutamate, such as occurs in ischemia. One possibility, however, is that a defect in mitochondrial energy metabolism could secondarily lead to slow excitotoxic neuronal death, by making neurons more vulnerable to endogenous glutamate. With reduced oxidative metabolism and partial cell membrane depolarization, voltage-dependent N-methyl-D-apartate (NMDA) receptor ion channels would be more easily activated. In addition, several other processes involved in buffering intracellular calcium may be impaired. Recent studies in experimental animals showed that mitochondrial toxins can result in a pattern of neuronal degeneration closely resembling that seen in Huntington's disease, which can be blocked with NMDA antagonists. NMDA antagonists also block neuronal degeneration induced by 1-methyl-4-phenylpyridium, which has been implicated in experimental models of Parkinson's disease. The delayed onset of neurodegenerative illnesses could be related to the progressive impairment of mitochondrial oxidative phosphorylation, which accompanies normal aging. If defective mitochondrial energy metabolism plays a role in cell death in neurodegenerative disorders, potential therapeutic strategies would be to use excitatory amino acid antagonists or agents to bypass bioenergetic defects.
References
- 1 Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988; 1: 623–634
- 2 Hatefi Y. Mitochondrial electron transport and oxidative phosphorylation system. Annu Rev Biochem 1985; 54: 1015–1069
- 3 Wallace DC. Mitochondrial genes and disease. Hosp Pract 1986; 21: 77–92
- 4 Hartl F-U, Pfanner N, Nicholson DW, Neupert W. Mitochondrial protein import. Biochim Biophys Acta 1989; 988: 1–45
- 5 Zeviani M, Servidei S, Gellera C, et al. An autosomal dominant disorder with multiple deletions of mitochondrial DNA starting at the D-loop region. Nature 1989; 339: 309–311
- 6 Zheng X, Shoffner JM, Lott MT, et al. Evidence in a lethal infantile mitochondrial disease for a nuclear mutation affecting respiratory complexes I and IV. Neurology 1989; 39: 1203–1209
- 7 Irwin CC, Wexler NS, Young AB, et al. The role of mitochondrial DNA in Huntington's disease. J Mol Neurosci 1989; 1: 129–136
- 8 Ridley RM, Frith CD, Farrer LA, Conneally PM. Patterns of inheritance of the symptoms of Huntington's disease suggestive of an effect of genomic imprinting. J Med Genet 1991; 28: 224–231
- 9 Kuhl DE, Phelps ME, Markham CH, et al. Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan. Ann Neurol 1982; 14: 425–434
- 10 Hayden MR, Martin WRW, Stoessel AJ, et al. Positron emission tomography in the early diagnosis of Huntington's disease. Neurology 1986; 36: 888–894
- 11 Mazziotta JC, Phelps ME, Pahl JI, et al. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. N Engl J Med 1987; 316: 356–362
- 12 Young AB, Penney JB, Starosta-Rubinstein S, et al. Normal caudate glucose metabolism in persons at risk for Huntington's disease. Arch Neurol 1987; 44: 254–257
- 13 Hayden MR, Hewitt J, Stoessel AJ, et al. The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington's disease. Neurology 1987; 37: 1441–1447
- 14 Grafton ST, Mazziotta JC, Pahl JJ, et al. A comparison of neurological, metabolic, structural and genetic evaluations in persons at risk for Huntington's disease. Ann Neurol 1990; 28: 614–621
- 15 Kuwert T, Lange HW, Langer K-J, et al. Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. Brain 1990; 113: 1405–1423
- 16 Sorbi S, Bird ED, Blass JP. Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain. Ann Neurol 1983; 13: 72–78
- 17 Butterworth J, Yates CM, Reynolds GP. Distribution of phosphate-activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase, and α-glutamyl transpeptidase in post-mortem brain from Huntington's disease and agonal cases. J Neurol Sci 1985; 67: 161–171
- 18 Mann VM, Cooper JM, Javoy-Agid F, et al. Mitochondrial function and parental sex effect in Huntington's disease. Lancet 1990; 336: 682
- 19 Parker WD, Boyson SJ, Luder AS, Parks JK. Evidence for a defect in NADH: ubiquinone oxidoreductase (complex I) in Huntington's disease. Neurology 1990; 40: 1231–1234
- 20 Brennan WA, Bird ED, Aprille JR. Regional mitochondrial respiratory activity in Huntington's disease brain. J Neurochem 1985; 44: 1948–1950
- 21 Morgan-Hughes JA, Schapira AHV, Cooper JM, Clark JB. Molecular defects of NADH-ubiquinone oxidoreductase (complex I) in mitochondrial diseases. J Bioenerg Biomembr 1988; 20: 365–382
- 22 O'Brien CF, Miller C, Goldblatt D, et al. Extraneuronal metabolism in early Huntington's disease. Ann Neurol 1990; 78: 300–301
- 23 DiMauro S, Bonilla F, Lee CP, et al. Luft's disease; further biochemical and ultrastructural studies of skeletal muscle in the second case. J Neurol Sci 1976; 27: 217–232
- 24 Luft R, Ikkos O, Palmieri G, et al. A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control—a correlated clinical, biochemical, and morphological study. J Clin Invest 1962; 41: 1776–1804
- 25 Duara R, Grady C, Haxby JV, et al. Positron emission tomography in Alzheimer's disease. Neurology 1986; 36: 879–887
- 26 Haxby JV, Grady CL, Duara R, et al. Neocortical metabolic abnormalities precede non-memory cognitive deficits in early Alzheimer-type dementia. Arch Neurol 1986; 43: 882–885
- 27 Yates CM, Butterworth J, Tennant ML, Gordon A. Enzyme activities in relation to pH and lactate in postmortem brain in Alzheimer-type and other dementias. J Neurochem 1990; 55: 1624–1630
- 28 Blass JP, Shen RK-F, Cedarbaum JM. Energy metabolism in disorders of the nervous system. Rev Neurol 1988; 144: 543–563
- 29 Parker WD, Filley CM, Parks JM. Cytochrome oxidase deficiency in Alzheimer's disease. Neurology 1990; 40: 1302–1303
- 30 Singer TP, Ramsey RR. Mechanism of the neurotoxicity of MPTP. FEBS Lett 1990; 274: 1–8
- 31 Furtado JCS, Mazurek MF. MPTP-induced neurotoxicity and the quest for a preventative therapy for Parkinson's disease. Can J Neurol Sci 1991; 18: 77–82
- 32 Ramsey RR, Krueger MJ, Youngster SK, et al. Interaction of 1-methyl-4-phenylpyridinium ion (MPP+) and its analogs with the rotenone/piericidin binding site of NADH dehydrogenase. J Neurochem 1991; 56: 1184–1190
- 33 Schapira AHV, Mann UM, Cooper JM, et al. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 1990; 55: 2142–2145
- 34 Schapira AHV, Cooper JM, Dexter D, et al. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990; 54: 823–827
- 35 Parker WD, Boyson SJ, Parks JK. Electron transport chain abnormalities in idiopathic Parkinson's disease. Ann Neurol 1989; 26: 719–723
- 36 Shoffner JM, Watts RL, Juncos JL, et al. Parkinson's disease: a systemic disorder of mitochondrial oxidative phosphorylation. Neurology 1991; 41 (suppl 1): 152
- 37 Mizuro Y, Ohta S, Tanaka M, et al. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 1989; 163: 1450–1455
- 38 Ikebe S, Tanaka M, Ohno K, et al. Increase of deleted mitochondrial DNA in the striatum in Parkinson's disease and senescence. Biochem Biophys Res Commun 1990; 170: 1044–1048
- 39 Ozawa T, Tanaka M, Ikebe S, et al. Quantitative determination of deleted mitochondrial DNA relative to normal DNA in parkinsonian striatum by a kinetic PCR analysis. Biochem Biophys Res Commun 1990; 172: 483–489
- 40 Lestienne P, Nelson I, Riederen P, et al. Mitochondrial DNA in postmortem brain from patients with Parkinson's disease. J Neurochem 1991; 56: 682
- 41 Linnane AW, Baumer A, Maxwell RJ, et al. Mitochondrial gene mutation: the aging process and degenerative diseases. Biochem Int 1990; 22: 1067–1076
- 42 Gilman S, Markel DS, Koeppe RA, et al. Cerebellar and brainstem hypometabolism in olivopontocerebellar atrophy detected with positron emission tomography. Ann Neurol 1988; 23: 223–230
- 43 Gilman S, Junck L, Markel DS, et al. Cerebral glucose hypermetabolism in Friedrich's ataxia detected with positron emission tomography. Ann Neurol 1990; 28: 750–757
- 44 Plaitakis A, Berl S, Yahr MD. Abnormal glutamate metabolism in an adult-onset degenerative neurological disorder. Science 1982; 216: 193–196
- 45 Hatazawa J, Brooks RA, Dalakas MC, et al. Cortical motorsensory hypometabolism in amyotrophic lateral sclerosis: a PET study. J Comput Assist Tomogr 1988; 12: 630–636
- 46 Dalakas MC, Hatazawa J, Brooks RA, DiChiro G. Lowered cerebral glucose utilization in amyotrophic lateral sclerosis. Ann Neurol 1987; 22: 580–586
- 47 Hurst EW. Experimental demyelination of the central nervous system. 3. Poisoning with potassium cyanide, sodium azide, hydroxylamine, narcotics, carbon monoxide, etc., with some consideration of bilateral necrosis occurring in the basal nuclei. Aust J Exp Biol Med Sci 1942; 20: 297–312
- 48 Miyoshi K. Experimental striatal necrosis induced by sodium azide. Acta Neuropathol (Berl) 1967; 9: 199–216
- 49 Hicks SP. Brain metabolism in vivo II. Arch Pathol 1950; 50: 545–561
- 50 Mettler FA. Choreoathetosis and striopallidal necrosis due to sodium azide. Exp Neurol 1972; 34: 291–308
- 51 Ludolph AC, Ludolph AG, Sabri MI, et al. 3-Nitropropionic acid-abundant xenobiotic excitotoxin linked to putaminal necrosis and tardive dystonia. Ann Neurol 1991; 30: 682
- 52 Gould DH, Gustine DL. Basal ganglia degeneration, myelin alterations, and enzyme inhibition induced in mice by the plant toxin 3-nitropropanoic acid. Neuropathol Appl Neurobiol 1982; 8: 377–393
- 53 Hamilton BF, Gould DH. Nature and distribution of brain lesions in rats intoxicated with 3-nitropropionic acid: a type of hypoxic (energy deficient) brain damage. Acta Neuropathol (Berl) 1987; 72: 286–297
- 54 Rosenberg NL, Myers JA, Martin WRW. Cyanide-induced parkinsonism: clinical, MRI, and 6-fluorodopa PET studies. Neurology 1989; 39: 142–144
- 55 Uitti RJ, Rajput AH, Ashenhurst EM, Rozdilsky B. Cyanide induced parkinsonism: a clinicopathologic report. Neurology 1985; 35: 921–925
- 56 Harding AE. Neurological disease and mitochondrial genes. Trends Neurosci 1991; 14: 132–138
- 57 Truong DD, Harding AE, Scaravelli F, et al. Movement disorders in mitochondrial myopathies. Mov Dis 1990; 5: 109–117
- 58 Wallace DC, Singh G, Lott MT, et al. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science 1988; 242: 1427–1430
- 59 Parker WD, Oley CA, Parks JK. A defect in mitochondrial electron-transport activity (NADH-coenzyme Q oxidoreductase) in Leber's hereditary optic neuropathy. N Engl J Med 1989; 320: 1331–1333
- 60 Novotny EJ, Singh G, Wallace DC, et al. Leber's disease and dystonia: a mitochondrial disease. Neurology 1986; 36: 1053–1060
- 61 Goto Y, Nonaka I, Horai S. A mutation in the tRNA Leu (UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 1990; 348: 651–653
- 62 Kobayashi Y, Momoi MY, Tominaga K, et al. A point mutation in the mitochondrial tRNA Leu (UUR) gene in MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes). Biochem Biophys Res Commun 1990; 173: 816–822
- 63 Shoffner JM, Lott MT, Lezza AMS, et al. Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNA Lys mutation. Cell 1990; 61: 931–937
- 64 Fukuhara N, Tokiguchi S, Shirakawak Tsubaki T. Myoclonus epilepsy associated with ragged-red fibers (mitochondrial abnormalities): disease entity or a syndrome. J Neurol Sci 1980; 40: 117–133
- 65 Berkovic SDF, Carpenter S, Evants A, et al. Myoclonus epilepsy and ragged-red fibers (MERRF). 1. A clinical, pathological, biochemical, magnetic resonance spectrographic and positron tomographic study. Brain 1989; 112: 1231–1260
- 66 Lombes A, Mendel JR, Nakase H, et al. Myoclonic epilepsy and ragged-red fibers with cytochrome oxidase deficiency: neuropathology, biochemistry, and molecular genetics. Ann Neurol 1989; 26: 20–33
- 67 Takeda S, Wakabayashi K, Ohama E, Ikuta F. Neuropathology of myoclonus epilepsy associated with ragged-red fibers (Fukuhara's disease). Acta Neuropathol (Berl) 1988; 75: 433–440
- 68 McKelvie PA, Morley JB, Byrne E, Marzuki S. Mitochondrial encephalomyopathies: a correlation between neuropathological findings and defects in mitochondrial DNA. J Neurol Sci 1991; 102: 51–60
- 69 Matthews PM, Berkovic SF, Shoubridge EA, et al. In vivo magnetic resonance spectroscopy of brain and muscle in a type of mitochondrial encephalomyopathy (MERRF). Ann Neurol 1991; 29: 435–438
- 70 Kuhn-Nentwig L, Kadenbach B. Isolation and properties of cytochrome c oxidase from rat liver and quantification of immunological differences between isoenzymes from various rat tissues with subunit-specific antisera. Eur J Biochem 1985; 149: 147–158
- 71 Ewart G, Lightowlers R, Zhang Y-Z, et al. Tissue specificity and defects in human cytochrome c oxidase. Biochem Biophys Acta 1990; 1018: 223–224
- 72 Kennaway NG, Carrero-Valenzuela RD, Ewart G, et al. Isoforms of mammalian cytochrome c oxidase: correlation with human cytochrome c oxidase deficiency. Pediatr Res 1990; 28: 529–535
- 73 Neckelmann N, Li K, Wade RP, et al. CDNA sequence of a human skeletal muscle ADP/ATP translocator: lack of a leader peptide, divergence from a fibroblast translocator cDNA, and coevolution with mitochondrial DNA genes. Proc Natl Acad Sci USA 1987; 84: 7580–7584
- 74 Houldsworth J, Atlardi G. Two distinct genes for ADP/ATP adult human liver. Proc Natl Acad Sci USA 1988; 85: 377–381
- 75 Moraes CT, Shanske S, Tritschler HJ, et al. Mtdna depletion with variable tissue expression: a novel genetic abnormality in mitochondrial diseases. Am J Hum Genet 1991; 48: 492–501
- 76 Howell N, Kubacka I, Xu M, McCullough DA. Leber hereditary optic neuropathy: involvement of the mitochondrial ND 1 gene and evidence for a intragenic suppressor mutation. Am J Hum Genet 1991; 48: 935–942
- 77 Olney JW. Brain lesion, obesity and other disturbances in mice treated with monosodium glutamate. Science 1969; 164: 719–721
- 78 Coyle JT, Schwarcz R. Lesions of striatal neurons with kainic acid provides a model for Huntington's chorea. Nature 1976; 263: 244–246
- 79 McGeer EG, McGeer PL. Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids. Nature 1976; 263: 517–519
- 80 Ferrante RJ. Kowall NW, Beal MF, et al. Selective sparing of a class of striatal neurons in Huntington's disease. Science 1987; 230: 561–563
- 81 Dawbarn D, DeQuidt ME. Emson PL. Survival of basal ganglia neuropeptide Y–somatostatin neurons in Huntington's disease. Brain Res 1985; 340: 251–260
- 82 Ferrante RJ, Beal MR, Kowall NW, et al. Sparing of acetyl-cholinesterase-containing striatal neurons in Huntington's disease. Brain Res 1987; 411: 162–166
- 83 Beal MF, Marshall PE, Burd GD, et al. Excitotoxin lesions do not mimic the alteration of somatostatin in Huntington's disease. Brain Res 1985; 361: 135–145
- 84 Schwarcz R, Whetsell WO, Mangano RM. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 1983; 219: 316–318
- 85 Beal MF, Kowall NW, Ellison DW, et al. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986; 321: 168–171
- 86 Beal MF, Kowall NW, Swartz KJ, et al. Differential sparing of somatostatin–neuropeptide Y and cholinergic neurons following striatal excitotoxic lesions. Synapse 1989; 3: 38–47
- 87 Davies SW, Roberts PJ. No evidence for preservation of somatostatin containing neurons after intrastriatal injections of quinolinic acid. Nature 1987; 327: 326–329
- 88 Boegman RJ, Smith Y, Parent A. Quinolinic acid does not spare striatal neuropeptide Y–immunoreactive neurons. Brain Res 1987; 415: 178–182
- 89 Koh J-Y, Choi DW. Cultured striatal neurons containing NADPH-diaphorase or acetylcholinesterase are selectively resistant to injury by NMDA receptor agonists. Brain Res 1988; 46: 374–378
- 90 Koh JY, Peters S, Choi DW. Neurons containing NADPH-diaphorase are selectively resistant to quinolinate toxicity. Science 1986; 234: 73–76
- 91 Whetsell WO Jr, Christie-Pope B. Relative resistance to quinolinic acid toxicity of neurons containing nicotinamide adenine dinucleotide phosphate diaphorase (NADPH-d) in cultures of rat corticostriatal system. Soc Neurosci Abstr 1988; 14: 682
- 92 Beal MF, Kowall NW, Swartz KJ, Ferrante RJ. Homocysteic acid striatal lesions spare somatostatin–neuropeptide Y–NADPH-diaphorase neurons. Neurosce Lett 1990; 108: 36–42
- 93 Beal MF, Kowall NW, Ferrante RJ, Cippolloni PB. Quinolinic acid striatal lesions in primates as a model of Huntington's disease. Ann Neurol 1989; 26: 682
- 94 Beal MF, Ferrante RJ, Swartz KJ, Kowall NW. Chronic quinolinic acid lesions in rats closely mimic Huntington's disease. J Neurosci 1991; 11: 1649–1659
- 95 Waldvogel HJ, Faull RLM, Williams MN, Dragunow M. Differential sensitivity of calbindin and parvalbumin immunore-active cells in the striatum to excitotoxins. Brain Res 1991; 546: 329–335
- 96 Harrington KM, Kowall NW. Parvalbumin immunoreactive neurons resist degeneration in Huntington's disease striatum. J Neuropathol Exp Neurol 1991; 50: 682
- 97 Masuo Y, Montagne M-N, Pelaprat D, et al. Regulation of neurotensin-containing neurons in the rat striatum, effects of unilateral striatal lesions with quinolinic acid and ibotenic acid on neurotensin content and its binding site density. Brain Res 1990; 520: 6–13
- 98 Greenamyre JT, Young AB. Synaptic localization of striatal NMDA, quisqualate and kainate receptors. Neurosci Lett 1989; 101: 133–137
- 99 Hruska RE, Schwarcz R, Coyle JT, Yamamura HI. Alterations of muscarinic cholinergic receptors in the rat striatum after kainic acid injections. Brain Res 1978; 152: 620–625
- 100 Joyce JN, Marshal JF. Quantitative autoradiography of quinolinic acid D2 sites in rat caudate-putamen: localization to intrinsic neurons and not to neocortical afferents. Neuroscience 1987; 20: 773–795
- 101 Schwarcz R, Bennett JP, Coyle JT. Loss of striatal serotonin synaptic receptor binding induced by kainic acid lesions: correlations with Huntington's disease. J Neurochem 1977; 28: 867–869
- 102 Schwarcz R, Fuxe K, Hokfelt T, et al. Effects of chronic striatal kainate lesions on some dopaminergic parameters and enkephalin immunoreactive neurons in the basal ganglia. J Neurochem 1980; 34: 772–778
- 103 Young AB, Pan HS, Ciliax BJ, Penney JB. GABA and benzodiazepine receptors in basal ganglia function. Neurosci Lett 1984; 47: 361–367
- 104 Zaczek R, Schwarcz R, Coyle JT. Long-term sequelae of striatal kainate lesions. Brain Res 1978; 152: 626–632
- 105 Isacson O, Brundin P, Kelly PAT, et al. Functional neuronal replacment of grafted striatal neurons in the ibotenic acid–lesioned rat striatum. Nature 1984; 311: 458–460
- 106 Isacson O, Dunnett SB, Bjorklund A. Graft-induced behavioral recovery in an animal model of Huntington's disease. Proc Natl Acad Sci USA 1986; 83: 2728–2732
- 107 Sanberg PR, Calderon SF, Giordano M, et al. The QA model of Huntington's disease: locomotor abnormalities. Exp Neurol 1989; 105: 45–53
- 108 Sanberg PR, Lehmann J, Fibiger HC. Impaired learning and memory after kainic acid lesions of the striatum, a behavior model of Huntington's disease. Brain Res 1978; 149: 546–551
- 109 Deckel AW, Robinson RG, Coyle JT, Sanberg PR. Reversal of long-term locomotor abnormalities in the kainic acid model of Huntington's disease by day 18 fetal striatal implants. Eur J Pharmacol 1983; 93: 287–288
- 110 Hantraye P, Riche D, Maziere M, Isacson O. A primate model of Huntington's disease: behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen and in the baboon. Exp Neurol 1990; 108: 91–104
- 111 Kanazawa I, Tanaka Y, Cho F. Choreic movements induced by unilateral kainate lesion of the striatum and L-dopa administration in monkey. Neurosci Lett 1985; 71: 241–246
- 112 Young AB, Greenamyre JT, Hollingsworth Z, et al. NMDA receptor losses in putamen from patients with Huntington's disease. Science 1988; 241: 981–983
- 113 Dure LS, Penney JB, Young AB. Excitatory amino acid receptor populations in Huntington's disease. Soc Neurosci Abstr 1990; 16: 682
- 114 Albin RL, Young AB, Penney JB, et al. Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease. N Engl J Med 1990; 322: 1293–1298
- 115 Spencer PS, Nunn PB, Hugon S, et al. Guam amyotrophic lateral sclerosis–parkinsonism dementia linked to a plant excitant neurotoxin. Science 1987; 239: 517–522
- 116 Perry TL, Hansom S, Jones K. Brain glutamate deficiency in ALS. Neurology 1987; 37: 1845–1848
- 117 Rothstein JD, Tsai G, Kuncl RW, et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990; 28: 18–25
- 118 Plaitakis A, Constantakakis E, Smith T. The neuroexcitotoxic amino acids glutamate and aspartate are altered in the spinal cord and brain in amyotrophic lateral sclerosis. Ann Neurol 1988; 24: 446–449
- 119 Perry TL, Krieger C, Hansen S, Eisen A. Amyotrophic lateral sclerosis: amino acid levels in plasma and cerebrospinal fluid. Ann Neurol 1990; 28: 12–17
- 120 Yanker BA, Duffy LK, Kinschner DA. Neurotrophic and neurotoxic effects of amyloid β protein: reversal by tachykinin neuropeptides. Science 1990; 250: 279–282
- 121 Kowall NW, Beal MF, Busciglio J, et al. Neurodegenerative effects of β amyloid in the adult brain and protection by substance P. Proc Natl Acad Sci USA 1991; 88: 7247–7251
- 122 Koh J-Y, Yang LL, Cotman CW. β-Amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res 1990; 533: 315–320
- 123 Kowall NW, Beal MF. Glutamate, glutaminase and taurine immunoreactive neurons develop neurofibrillary tangles in Alzheimer's disease. Ann Neurol 1991; 29: 162–167
- 124 Rogers J, Morrison JH. Quantitative morphology and regional laminar distributions of senile plaques in Alzheimer's disease. J Neurosci 1985; 5: 2801–2808
- 125 Pearson RCA, Esiri MM, Hiorns RW, et al. Anatomical correlates of the pathological changes in the neocortex in Alzheimer's disease. Proc Natl Acad Sci USA 1985; 82: 4531–4534
- 126 Greenamyre JT, Penney JB, Young AB, et al. Alterations in L-glutamate binding in Alzheimer's and Huntington's disease. Science 1985; 227: 1496–1499
- 127 Greenamyre JT, Penney JB, D'Amato CJ, Young AB. Dementia of the Alzheimer's type: changes in hippocampal L-[3H] glutamate binding. J Neurochem 1987; 48: 543–551
- 128 Richter C, Park J-W, Ames BN. Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc Natl Acad Sci USA 1988; 85: 6465–6467
- 129 Linnane AW, Marzuki S, Ozawa T, Tanaka M. Mitochondrial DNA mutations as an important contribution to aging and degenerative diseases. Lancet 1989; 1: 642–645
- 130 Trounce I, Byrne E, Marzuki S. Decline in skeletal muscle mitochondrial respiratory chain function: possible factor in aging. Lancet 1989; 1: 637–639
- 131 Siesjo BK, Bengtsson F. Calcium fluxes, calcium antagonists, and calcium-related pathology in brain ischemia, hypoglycemia and spreading depression: a unifying hypothesis. J Cereb Blood Flow Metab 1989; 9: 127–140
- 132 Blaustein MP. Calcium transport and buffering in neurons. Trends Neurosci 1988; 11: 438–443
- 133 Choi DW. Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage. Trends Neurosci 1988; 11: 465–469
- 134 Novelli A, Reilly JA, Lysko PG, Henneberry RC. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res 1988; 451: 205–212
- 135 Olney JW, Price MT, Samson L, LeBruyere J. The role of specific ions in glutamate neurotoxicity. Neurosci Lett 1986; 65: 65–71
- 136 Abele AE, Miller RJ. Potassium channel activators abolish excitotoxicity in cultured hippocampal pyramidal neurons. Neurosci Lett 1990; 115: 195–200
- 137 Zeevalk GD, Nicklas WJ. Chemically induced hypoglycemia and anoxia: relationship to glutamate receptor-mediated toxicity in retina. J Pharmacol Exp Ther 1990; 253: 1285–1292
- 138 Zeevalk GD, Nicklas WJ. Mechanisms underlying initiation of excitotoxicity associated with metabolic inhibition. J Pharmacol Exp Ther 1991; 257: 870–878
- 139 Sah P, Hestrin S, Nicoll RA. Tonic activation of NMDA receptors by ambient glutamate enhances excitability of neurons. Science 1989; 246: 815–818
- 140 LoTurco JJ, Mody I, Kriegstein AR. Differential activation of glutamate receptors by spontaneously released transmitter in slices of cortex. Neurosci Lett 1990; 114: 265–271
- 141 Turski WA, Gramsbergen JBP, Traitler H, Schwarcz R. Rat brain slices produce and liberate kynurenic acid upon exposure to L-kynurenine. J Neurochem 1989; 52: 1629–1636
- 142 Swartz KJ, During MJ, Freese A, Beal MF. Cerebral synthesis and release of kynurenic acid, an endogenous antagonist of excitatory amino acid receptors. J Neurosci 1990; 10: 2965–2973
- 143 Beal MF, Swartz KJ, Hyman BT, et al. Aminooxyacetic acid results in excitotoxin lesions by a novel indirect mechanism. J Neurochem 1991; 57: 1068–1073
- 144 Jenkins BG, Storey E, Beal MF, Rosen BR. Chemical shift imaging of focal neurochemical lesions in rat brains. Soc Magn Reson Med 1991; 1: 682
- 145 Palaiplogos G, Hertz L, Schousboe A. Evidence that aspartate aminotransferase activity and ketodicarboxylate carrier function are essential for the biosynthesis of transmitter glutamate. J Neurochem 1988; 51: 317–320
- 146 Cheeseman AJ, Clark JB. Influence of the malate-aspartate shuttle on oxidative metabolism in synaptosomes. J Neurochem 1988; 50: 1559–1565
- 147 Lehninger AL. Phosphorylation coupled to oxidation of dihydrodiphosphopyridine nucleotide. J Biol Chem 1951; 190: 345–359
- 148 Fitzpatrick SM, Cooper AJL, Duffy TE. Use of β-methylene-D, L-aspartate to assess the role of aspartate aminotransferase in cerebral oxidative metabolism. J Neurochem 1983; 41: 1370–1383
- 149 Kauppinen RA, Sihra TS, Nicholls DG. Aminooxyacetic acid inhibits the malate-aspartate shuttle in isolated nerve terminals and prevents the mitochondria from utilizing glycolytic substrates. Biochem Biophys Acta 1987; 930: 173–178
- 150 Urbanska E, Ikonomidou C, Sielucka M, Turski WA. Amino-oxyacetic acid produces excitotoxic lesions in the rat striatum. Soc Neurosci Abstr 1989; 15: 682
- 151 Bloem BR, Irwin I, Buruma OJS, et al. The MPTP model: versatile contributions to the treatment of idiopathic Parkinson's disease. J Neurol Sci 1990; 97: 273–293
- 152 Herkenhem M, Little MD, Bankiewicz K, et al. Selective retention of MPP+ within the monoamine systems of the primate brain following MPTP administration: an in vivo autoradiographic study. Neuroscience 1991; 40: 133–158
- 153 Chen P, DeLanney LE, Irwin I, et al. Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain. J Neurochem 1991; 57: 348–351
- 154 Turski L, Bressler K, Rettig K-J, et al. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature 1991; 349: 414–418
- 155 Storey E, Hyman BT, Miller JM, Beal MF. MPP+ produces excitotoxic lesions in rats. Soc Neurosci Abstr 1991; 17: 682
- 156 Hakim AM, Pappius HM. Sequence of metabolic, clinical, and histological events in experimental thiamine deficiency. Ann Neurol 1983; 13: 365–375
- 157 Parker WD, Haas R, Stumpf DA, et al. Brain mitochondrial metabolism in experimental thiamine deficiency. Neurology 1984; 34: 1477–1481
- 158 Langlais PJ, Mair RG. Protective effects of the glutamate antagonist MK-801 on pyrimethamine-induced lesions and amino acid changes in rat brain. J Neurosci 1990; 10: 1664–1674
- 159 Michenfelder JD, Milde JH, Sundt TM Jr. Cerebral protection by barbiturate anesthesia after middle cerebral artery occlusion in Java monkeys. Arch Neurol 1976; 33: 345–350
- 160 Selman WR, Spetzler RF, Roessman UR, et al. Barbiturate-induced coma therapy for focal cerebral ischemia: effect after temporary and permanent MCA occlusions. J Neurosurg 1981; 55: 220–226
- 161
Sanchez-Ramos JR,
Hefti F,
Hollinden GE, et al.
Mechanisms of MPP+ neurotoxicity: oxyradical and mitochondrial inhibitor hypotheses. In:
F Hefti,
WJ Weiner, eds.
Progress in Parkinson's research.
New York:
Plenum Press,
1988:
145–152
10.1007/978-1-4613-0759-4_18 Google Scholar
- 162 Ferriro DM, Arcavi LJ, Sagar SM, et al. Selective sparing of NADPH-diaphorase neurons in neonatal hypoxia-ischemia. Ann Neurol 1988; 24: 670–676
- 163 Uemura Y, Kowall NW, Beal MF. Selective sparing of NADPH-diaphorase–somatostatin–neuropeptide Y neurons in ischemic gerbil striatum. Ann Neurol 1990; 27: 620–625
- 164 Chesselet M-F, Gonzales C, Lin C-S, et al. Ischemic damage in the striatum of adult gerbils: relative sparing of somatostatinergic and cholinergic neurons contrasts with loss of efferent neurons. Exp Neurol 1990; 110: 209–218
- 165 Pryzyrembel H. Therapy of mitochondrial disorders. J Inherited Metab Dis 1987; 10: 129–146
- 166 Nishikawa Y, Takahasi M, Yorifuji S, et al. Long-term coenzyme Q10 therapy for a mitochondrial encephalomyopathy with cytochrome c oxidase deficiency. Neurology 1989; 39: 399–403
- 167 Ihara Y, Namba R, Kuroda S, et al. Mitochondrial encephalomyopathy (MELAS): pathological study and successful therapy with coenzyme Q10 and idebenone. J Neurol Sci 1989; 90: 263–271
- 168 Ichiki T, Tanaka M, Nishikimi M, et al. Deficiency of subunits of complex I and mitochondrial encephalomyopathy. Ann Neurol 1988; 23: 287–294
- 169 Bresolin N, Doriguzzi C, Ponzetto C. Ubidecarenone in the treatment of mitochondrial myopathies: a multi-center double-blind trial. J Neurol Sci 1990; 100: 70–78
- 170 Wijburg FA, Barth PG, Ruitenbeek W, et al. Familial NADH: Q1 oxidorectase (complex I) deficiency: variable expression and possible treatment. J Inherited Metab Dis 1989; 12: 349–351
- 171 Bernsen PLJA, Gabreels FJM, Ruitenbeek W, et al. Successful treatment of pure myopathy, associated with complex I deficiency with riboflavin and carnitine. Arch Neurol 1991; 48: 334–338
- 172 Chci DW. Methods for antagonizing glutamate neurotoxicity. Cerebrovase Brain Metab Rev 1990; 2: 105–147
- 173 Chiamulera C, Costa S, Reggiani A. Effect of NMDA and strychnine-insensitive glycine site antagonists on NMDA-mediated convulsions and learning. Psychopharmacology 1990; 102: 551–552
- 174 Koek W, Colpaert C. Selective blockade of N-methyl-D-aspartate (NMDA)-induced convulsions by NMDA antagonists and putative glycine antagonists: relationship with phencyclidine-like behavioral effects. J Pharmacol Exp Ther 1990; 252: 349–357